SML0472
4-IPP
≥97% (HPLC)
Sinónimos:
4-Iodo-6-phenylpyrimidine
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Fórmula empírica (notación de Hill):
C10H7IN2
Número de CAS:
Peso molecular:
282.08
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Productos recomendados
Quality Level
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL (clear solution, warmed)
storage temp.
−20°C
SMILES string
Ic1cc(ncn1)-c2ccccc2
InChI
1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H
InChI key
ZTCJXHNJVLUUMR-UHFFFAOYSA-N
Application
4-IPP has been used as a macrophage migration inhibitory factor (MIF) in conditioned medium (CM) for in vitro migration assay.
Biochem/physiol Actions
4-IPP is a cell permeable, potent macrophage migration inhibitory factor (MIF) antagonist that covalently modifies MIF N-terminal proline.
4-Iodo-6-phenylpyrimidine (4-IPP) has the potential to be a new anti-polyploid therapeutic agent that may be utilized in patients with thyroid cancer to target polyploid tumor cells. It suppresses osteoclastogenesis by blocking the IMF-κB pathway. 4-IPP can be employed as a therapeutic target for macrophage migration inhibitory factor (MIF) to treat pathologic osteolytic bone diseases and postmenopausal bone loss. It can prevent the development and motility of lung adenocarcinoma cells and can stimulate apoptosis and mitotic death of thyroid carcinomas.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
¿No ve la versión correcta?
Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Sarah Maria Johler et al.
Cancer immunology, immunotherapy : CII, 65(12), 1465-1476 (2016-09-16)
Macrophage migration inhibitory factor (MIF) is known to be involved in oncogenic transformation, tumour progression, and immunosuppression and is overexpressed in many solid tumours, including paediatric rhabdomyosarcoma (RMS). We investigated the function of MIF in RMS during treatment with cytotoxic
Yuxin Zhang et al.
Aging, 13(4), 5804-5823 (2021-02-19)
Joint capsule fibrosis caused by excessive inflammation leading to post-traumatic joint contracture (PTJC). Fibroblasts trigger inflammation under the challenge of various proinflammatory cytokines. Macrophage migration inhibitory factor (MIF) is a prominent proinflammatory cytokine involved in inflammation- and fibrosis-associated pathophysiology, we
Kavitha Yaddanapudi et al.
Cancer immunology research, 4(2), 101-112 (2015-11-26)
Highly aggressive cancers "entrain" innate and adaptive immune cells to suppress antitumor lymphocyte responses. Circulating myeloid-derived suppressor cells (MDSC) constitute the bulk of monocytic immunosuppressive activity in late-stage melanoma patients. Previous studies revealed that monocyte-derived macrophage migration inhibitory factor (MIF)
Nadège Kindt et al.
Journal of clinical medicine, 8(1) (2019-01-13)
Human papilloma virus (HPV) infection has been well-established as a risk factor in head and neck squamous cell carcinoma (HNSCC). The carcinogenic effect of HPV is mainly due to the E6 and E7 oncoproteins, which inhibit the functions of p53
Seul-Ki Cheon et al.
Molecular oncology, 12(8), 1398-1409 (2018-06-14)
Although MEK blockade has been highlighted as a promising antitumor drug, it has poor clinical efficacy in KRAS mutant colorectal cancer (CRC). Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico